{
    "nctId": "NCT05625698",
    "briefTitle": "Premarking of Axillary Nodes Before Start of Neoadjuvant Chemotherapy Using Magnetic Approach",
    "officialTitle": "Axillary Lymph Node Identification Before Neoadjuvant Chemotherapy Using MagTrace (Superparamagnetic Iron Oxide Nanoparticles, SPIO) and Magseed, in Clinically Node Negative and Node Positive Patients: a Feasibility Study.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Detection rate of axillary sentinel node after neoadjuvant chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* A patient meeting the following criteria is eligible for participation in the study:\n* Patients 18 years of age or older\n* Patients with breast cancer planned to undergo preoperative chemotherapy (NACT) with a) planned sentinel lymph node biopsy (SNB) or b) axillary lymph node dissection, in conjunction with the beast surgery after NACT\n\nExclusion Criteria:\n\n* Intolerance / hypersensitivity to iron or dextran compounds or SPIO.\n* Patients who are required to undergo MR to evaluate tumour response\n* Pregnancy or breast feeding\n* Patients with an iron overload disease.\n* Patient deprived of liberty or under guardianship.\n* Inability to understand given information, give informed consent, undergo study procedures\n* MRI (subgroup of patients): Conditions contraindicating MRI including, but not limited to, BMI \\> 40 kg/m2, claustrophobia, metallic implants or internal electrical devices (e.g. Pacemaker).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}